- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
[VIRTUAL] Optimal Utilisation of Statins in Real-World Settings () - May 18, 2020 - Abstract #ADA2020ADA_2361;
In the population between 40 and 75, a majority were on low-intensity statins with relatively very few progressing to moderate and high-intensity statin. The low uptake of statins and low dose use indicates the need to increase awareness of appropriate patient selection and correct dose of statin use in the clinic population including referral and tertiary care clinics.
- |||||||||| Veramyst (fluticasone furoate nasal spray) / GSK
Review, Journal: Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease. (Pubmed Central) - May 14, 2020
Studies comparing the effect and safety of other ICSs such as fluticasone furoate and beclomethasone are too few to draw firm conclusions from...The indication of using ICS in COPD is stronger if the patient has increased blood eosinophils levels. There are data indicating that the choice of ICS matters, with studies showing a better effect-safety profile with budesonide compared to fluticasone propionate whereas it is not possible to make benefit-risk comparisons between the other licensed ICSs.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi, sirolimus / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
First report of post‐transplant autoimmune hyperlipidaemia and treatment with rituximab () - May 14, 2020 - Abstract #BSH2020BSH_100;
Our case is the first reported case of such an autoimmune phenomenon post‐allograft. Further work is required to elucidate the frequency of such autoimmune phenomenon in the transplant population.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: PPARα suppresses Th17 cell differentiation through IL-6/STAT3 /RORγt pathway in experimental autoimmune myocarditis. (Pubmed Central) - May 11, 2020
Importantly, in vivo activation of PPARα ameliorates EAM by suppressing Th17 cell differentiation through reducing the expression of RORγt and phosphorylated STAT3 that are upregulated in EAM hearts. These results imply that PPARα suppresses Th17 cell differentiation through IL-6/STAT3/RORγt signaling pathway and suggest that PPARα may become a molecular target for treating autoimmune myocarditis.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Clinical, Journal: EFFICACY OF INSULIN, HEPARIN AND FENOFIBRATE COMBINATION TREATMENT IN SEVERE HYPERTRIGLYCERIDEMIA: DOUBLE CENTER EXPERIENCE. (Pubmed Central) - May 8, 2020
Potential toxicities related to insulin, heparin and fenofibrate combination treatment including hypoglycemia, hemorrhage, rise in creatine kinase levels, hepato - and nephrotoxicity were not observed. In this trial involving patients with SH, our data suggest that insulin, heparin and fenofibrate combination therapy was safe and effective.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Preclinical, Journal: Red cabbage (Brassica oleracea L.) extract reverses lipid oxidative stress in rats. (Pubmed Central) - May 1, 2020
Herein, we investigated the effect of red cabbage aqueous extract (RC) or fenofibrate (FF) in oxidative stress induced by Triton WR-1339 in rats...The TBARS and PC levels increased in the liver, cerebral cortex and hippocampus of hyperlipidemic rats were decreased by the treatments with RC or FF. These findings demonstrated that RC is a potential therapy to treat diseases not only involving dyslipidemic condition but also oxidative stress.
- |||||||||| Clinical, Journal: Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice. (Pubmed Central) - May 1, 2020
In terms of lipid-lowering medication, statins improve EF in subjects with DM, while data from short-term trials suggest that fenofibrate improves EF; ezetimibe also improves EF but further studies are required in people with DM...Clopidogrel improves EF, but more studies in subjects with DM are required...Phosphodiesterase type 5 inhibitors improve endothelial function locally in the corpus cavernosum. Finally, cilostazol exerts favorable effect on EF, nevertheless, more data in people with DM are required.
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Journal: Abnormal Presentation of Hypoxic Ischemic Encephalopathy Attributed to Polysubstance Exposure. (Pubmed Central) - Apr 26, 2020
Clonidine was used to control the NAS symptoms, ranitidine was used to treat the gastroesophageal reflux, and glycopyrronium bromide was used for the neonate's excessive secretions. After delivery, the patient was placed on a nasal noninvasive cannula for respiratory distress and was transferred to a different hospital for treatment of the more serious comorbid conditions.
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Clinical, Review, Journal: Pharmacology, toxicology and clinical safety of glycopyrrolate. (Pubmed Central) - Apr 14, 2020
More recently, topical formulations of glycopyrrolate (GPB, also known as glycopyrronium bromide) have gained interest as a treatment option for excessive sweating (hyperhidrosis)...The information on the nonclinical and clinical safety profile of glycopyrronium supporting various therapeutically approved uses has been obtained from published literature, our own data as well as summary documents issued by regulatory bodies. Collectively, these data support the conclusion that the benefits of glycopyrronium generally outweigh the risks in chronic use indications that require muscarinic receptor antagonism to provide therapeutic effects.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Formononetin ameliorates cholestasis by regulating hepatic SIRT1 and PPARα. (Pubmed Central) - Apr 12, 2020
Moreover, formononetin attenuated ANIT-induced inflammatory response by inactivating JNK inflammation pathway in PPARα dependent manner. Taken together, our study demonstrates that formononetin ameliorates hepatic cholestasis by upregulating expression of SIRT1 and activating PPARα, which is an important anti-cholestatic mechanism of formononetin.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Pathogenesis, histopathologic findings and treatment modalities of lipoprotein glomerulopathy: A review. (Pubmed Central) - Apr 10, 2020
LPG treatment includes fenofibrate, antilipidemic drugs, steroids, LDL aphaeresis, plasma exchange, antiplatelet drugs, anticoagulants, urokinase, and renal transplantation. Recurrence in kidney graft suggests a pathogenic component(s) of extraglomerular humoral complex resulting from abnormal lipoprotein metabolism and presumably associated to ApoE.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Severe Combined Dyslipidemia With a Complex Genetic Basis. (Pubmed Central) - Apr 10, 2020
Conclusion. The multiple genetic "hits" on top of the classical APOE E2/E2 genotype likely explain the more severe dyslipidemia and refractory clinical phenotype.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD). (Pubmed Central) - Apr 3, 2020
The multiple genetic "hits" on top of the classical APOE E2/E2 genotype likely explain the more severe dyslipidemia and refractory clinical phenotype. We have developed a co-assembled nanosystem based on fenofibrate and ketoprofen by tactfully utilizing their simultaneous benzophenone interaction, which greatly enhances the bioavailability of fenofibrate and plays a role in the dual-targeted treatment of NAFLD by reducing hepatic lipid accumulation and inflammatory responses.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi, metformin / Generic mfg.
Asparaginase Induced Severe Hypertriglyceridemia Requiring Multiple Plasmapheresis Sessions (ENDOExpo) - Apr 1, 2020 - Abstract #ENDO2020ENDO_3803;
This side effect may be explained by multiple mechanisms including increased synthesis of very low-density lipoprotein (VLDL), decreased LPL activity as a result of an increase in the apoCIII/apoCII ratio, and increase in serum chylomicrons. Studies have shown patients who had extreme HTG had a higher frequency of ApoE3/4 phenotype, suggesting that screening for ApoE polymorphism may identify patients at high risk for developing this.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi, cyclophosphamide intravenous / Generic mfg.
Preclinical, Journal: Nerolidol attenuates cyclophosphamide-induced cardiac inflammation, apoptosis and fibrosis in Swiss Albino mice. (Pubmed Central) - Mar 24, 2020
Histopathological analysis (H & E and Masson's trichrome staining); ultrastructural analysis (transmission electron microscopy) and immunohistochemical analysis were also performed along with mRNA expression and molecular docking to establish the cardioprotective potential of nerolidol. Nerolidol acted as a potent cardioprotective molecule and attenuated CP-induced cardiotoxicity.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Preclinical, Journal: Antiobesity, Regulation of Lipid Metabolism, and Attenuation of Liver Oxidative Stress Effects of Hydroxy-α-sanshool Isolated from Zanthoxylum bungeanum on High-Fat Diet-Induced Hyperlipidemic Rats. (Pubmed Central) - Mar 22, 2020
Wistar rats (n = 48) were randomly divided into six groups: (1) normal diet rats (ND), (2) high-fat diet- (HFD-) treated rats, (3) HFD+fenofibrate-treated rats (HFD+FNB), (4) HFD+low dose of HAS-treated rats (HFD+LD, 9 mg/kg), (5) HFD+middle dose of HAS-treated rats (HFD+MD, 18 mg/kg), and (6) HFD+high dose of HAS-treated rats (HFD+HD, 36 mg/kg)...Immunohistochemistry and Western blotting indicated that HAS stimulation increased the levels of PPARγ and APOE in the liver, as a stress response of the body defense system. These results revealed that HAS exerts antiobesity and hypolipidemic activities in HFD rats by reducing liver oxidative stress and thus could be considered as a potential candidate drug to cure or prevent obesity and hyperlipidemia.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: A Protective Effect of PPARα in Endothelial Progenitor Cells Through Regulating Metabolism. (Pubmed Central) - Mar 19, 2020
Fenofibrate, an agonist of peroxisome proliferator-activated receptor α (PPARα), has shown therapeutic effects on DR in both patients and diabetic animal models...These findings suggest that PPARα is an endogenous regulator of ECFC/CAC metabolism and cell fate. Diabetes-induced down-regulation of PPARα contributes to ECFC/CAC deficiency and retinal vascular degeneration in DR.
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Possible Low-Value Medication Use by Persons with Idiopathic Pulmonary Fibrosis (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area K) - Mar 15, 2020 - Abstract #ATS2020ATS_9137;
One hundred seventeen (117, 28%) persons were first treated with a proton pump inhibitor following IPF diagnosis. Two hundred eleven (211, 50%) persons used a SABA.
- |||||||||| glycopyrrolate/indacaterol/mometasone (QVM149) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
Real-Life Treatment Patterns and Burden of Disease Among Patients with COPD - A Large Observational Study (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area H) - Mar 15, 2020 - Abstract #ATS2020ATS_6635;
Overall, 27% of COPD patients had a record for at least one moderate-severe exacerbation during the 1-year post index, of which 65% had no maintenance treatment at index.CONCLUSIONSIn this real-life study, including incident and prevalent cases with a registered COPD diagnosis, more than two thirds of patients had no claims of any maintenance treatment at index. Exacerbation frequency was considerable during the year post index, indicating a remaining unmet medical need in the diagnosis and management of COPD.
- |||||||||| glycopyrrolate/indacaterol/mometasone (QVM149) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
Trioptimize V: Improvement of Air Flow and Resistance in Patients with COPD Treated with Extrafine Single Inhaler Triple Therapy in a Real-World Setting (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area H) - Mar 15, 2020 - Abstract #ATS2020ATS_6626;
Summary and Conclusion This interim analysis reports that after 6 months of treatment with extrafine SITT (BDP/FF/G) in symptomatic patients with moderate to severe COPD, improvement in airflow obstruction and airway resistance was evident in those on prior ICS/LABA with expected limited improvement in those on MITT. These therapeutic benefits on efSITT are consistent with the results from two published RCTs, TRILOGY and TRINITY, respectively.
- |||||||||| glycopyrrolate/indacaterol/mometasone (QVM149) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
Characterization of Severe Asthma Patients Affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area E) - Mar 15, 2020 - Abstract #ATS2020ATS_5558;
A small proportion of patients were identified using maximum bronchodilation (ICS/LABA+LAMA). The characterization of these patients is relevant for both patients and HMO, who can improve disease management strategies to leverage patient care.
- |||||||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Patients' Preference and Choice of Pressurized Metered-Dose Inhalers (pMDIs) in Korean Asthmatics (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area K) - Mar 15, 2020 - Abstract #ATS2020ATS_4977;
Asthma treatment outcomes did not differ between two pMDIs. However, patients preferred BDP-FOR to FP-FOR in terms of size, design, grip and ease of use, which is somewhat different from expectation of health care providers.
- |||||||||| glycopyrrolate/indacaterol/mometasone (QVM149) / Novartis
Treatment Patterns and Disease Burden of Triple Therapy in Asthma (PENNSYLVANIA CONVENTION CENTER, Room 204 A-B (200 Level)) - Mar 15, 2020 - Abstract #ATS2020ATS_4709;
Patients using triple therapy had low adherence and persistence to MITT. Adherence to each individual triple therapy component was demonstrably higher, suggesting that patients are not using all three therapy components simultaneously.
- |||||||||| glycopyrrolate/indacaterol/mometasone (QVM149) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
Prescribing Pathways from Initial Medication Use to Triple Therapy in COPD: A Real-World Population Study (PENNSYLVANIA CONVENTION CENTER, Room 126 A-B (100 Level)) - Mar 15, 2020 - Abstract #ATS2020ATS_4303;
Half of persons with COPD who end up on triple therapy get there around one year after diagnosis. COPD medication regimens not recommended by guidelines were observed.
- |||||||||| glycopyrrolate/indacaterol/mometasone (QVM149) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
Trioptimize VI: The Use of Extrafine Single Inhaler Triple Therapy Improves Adherence to Treatment in Patients with COPD - Real-World Evidence (PENNSYLVANIA CONVENTION CENTER, Room 204 A-B (200 Level)) - Mar 15, 2020 - Abstract #ATS2020ATS_3374;
Summary and Conclusion These results indicate that in a real-world setting, switching patients with moderate to severe COPD symptomatic on ICS/LABA or MITT to extrafine SITT with BDP/FF/G is associated with improved adherence to treatment. Further in-depth analysis is planned to describe the different types of adherence impairment (e.g. sporadic/deliberate/unconscious) and to better understand the relationship between improved TAI scores and clinical and health status endpoints.
|
